These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 29211820)
1. Economic Impact of a Preferred Anti-Methicillin Susceptible Staphylococcus aureus Protocol. Gauthier TP; Carrasquillo M; Lichtenberger P; Baracco G Clin Infect Dis; 2018 Apr; 66(9):1483-1484. PubMed ID: 29211820 [No Abstract] [Full Text] [Related]
2. Definitive Treatment for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Data Versus a Definitive Answer? Karchmer AW Clin Infect Dis; 2017 Jul; 65(1):107-109. PubMed ID: 28379366 [No Abstract] [Full Text] [Related]
3. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study. McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314 [TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Beganovic M; Cusumano JA; Lopes V; LaPlante KL; Caffrey AR Open Forum Infect Dis; 2019 Jul; 6(7):ofz270. PubMed ID: 31281864 [TBL] [Abstract][Full Text] [Related]
5. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia. Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442 [TBL] [Abstract][Full Text] [Related]
6. Methicillin-Susceptible Staphylococcus Aureus Bacteremia: Cefazolin in Prime But Nafcillin Not Ready for an Exit. Sarria JC Am J Med Sci; 2020 Jul; 360(1):3-4. PubMed ID: 32439151 [No Abstract] [Full Text] [Related]
7. The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections. Flynt LK; Kenney RM; Zervos MJ; Davis SL Infect Dis Ther; 2017 Jun; 6(2):225-231. PubMed ID: 28265972 [TBL] [Abstract][Full Text] [Related]
8. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center. Pollett S; Baxi SM; Rutherford GW; Doernberg SB; Bacchetti P; Chambers HF Antimicrob Agents Chemother; 2016 Aug; 60(8):4684-9. PubMed ID: 27216053 [TBL] [Abstract][Full Text] [Related]
9. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections. Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335 [TBL] [Abstract][Full Text] [Related]
10. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea. Lee S; Song KH; Jung SI; Park WB; Lee SH; Kim YS; Kwak YG; Kim YK; Kiem SM; Kim HI; Kim ES; Park KH; Kim NJ; Jang HC; Kim HB; Clin Microbiol Infect; 2018 Feb; 24(2):152-158. PubMed ID: 28694202 [TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253 [TBL] [Abstract][Full Text] [Related]
12. [Cefazolin: a well-tolerated treatment for methicillin-susceptible Staphylococcus aureus complicated bacteremia]. ; Valour F Med Mal Infect; 2015 Apr; 45(4):144-5. PubMed ID: 26020076 [No Abstract] [Full Text] [Related]
13. Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible Staphylococcus aureus Infections. Gandhi AM; Shah MD; Donohue LE; Cox HL; Eby JC Clin Infect Dis; 2021 Nov; 73(9):1650-1655. PubMed ID: 33905485 [TBL] [Abstract][Full Text] [Related]
14. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia. McConeghy KW; Bleasdale SC; Rodvold KA Clin Infect Dis; 2013 Dec; 57(12):1760-5. PubMed ID: 23985343 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study. Oh DH; Kim JJ; Kim J; Seong H; Lee SJ; Kim YC; Kim EJ; Jung IY; Jeong WY; Jeong SJ; Ku NS; Han SH; Choi JY; Song YG; Kim JM BMC Infect Dis; 2018 Jan; 18(1):60. PubMed ID: 29378565 [TBL] [Abstract][Full Text] [Related]
16. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation. Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive Hamad Y; Nickel KB; Olsen MA; George IA Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150 [TBL] [Abstract][Full Text] [Related]
18. Cefazolin therapy for methicillin-susceptible Staphylococcus aureus bacteremia in Japan. Shoji T; Hirai Y; Osawa M; Totsuka K J Infect Chemother; 2014 Mar; 20(3):175-80. PubMed ID: 24462449 [TBL] [Abstract][Full Text] [Related]
19. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Bauer KA; West JE; Balada-Llasat JM; Pancholi P; Stevenson KB; Goff DA Clin Infect Dis; 2010 Nov; 51(9):1074-80. PubMed ID: 20879856 [TBL] [Abstract][Full Text] [Related]